Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HY-072808 is a novel small molecule phosphodiesterase 4 (PDE4) inhibitor developed for topical treatment of mild to moderate atopic dermatitis. It acts by inhibiting PDE4, an enzyme involved in the inflammatory response, thereby reducing inflammation and pruritus associated with atopic dermatitis. The drug is formulated as an ointment and has demonstrated favorable safety, pharmacokinetics, and efficacy profiles in clinical studies involving both healthy subjects and patients with atopic dermatitis. After topical administration, systemic exposure is low, supporting its use for localized skin conditions[1][2][4][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HY-072808.